On Target: Using Trop-2-Directed Therapeutics for Urothelial Carcinoma 

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.
For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ZDU865. CME/NCPD/AAPA/IPCE credit will be available until June 25, 2025.
On Target: Integrating Trop-2-Directed Therapeutics for Urothelial Carcinoma With Precision
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity has been supported by an independent educational grant from Gilead Sciences, Inc.
Disclosure information is available at the beginning of the video presentation.